Table 2 Prognostic analysis of risk factors for respiratory infection-related mortality in the derivation group.
Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
Crude HR | 95% CI | P value | Adjusted HR | 95% CI | P value | |
Age ≥ 65 years | 4.46 | 1.95–12.9 | < 0.01 | 3.32 | 1.30–11.2 | 0.03 |
Sex, male | 5.01 | 2.86–9.03 | < 0.01 | 2.61 | 1.32–5.24 | < 0.01 |
Body Mass Index < 18.5 (N = 787) | 2.34 | 1.31–4.25 | < 0.01 | |||
Tuberculosis sequelae | 1.06 | 0.32–2.61 | 0.91 | |||
Interstitial pneumonia | 5.26 | 2.40–10.3 | < 0.01 | 2.42 | 0.97–5.42 | 0.04 |
COPD | 9.45 | 4.30–18.6 | < 0.01 | 2.07 | 0.76–5.11 | 0.13 |
Bronchial asthma | 3.30 | 0.99–8.11 | 0.02 | |||
Connective tissue diseases | 1.23 | 0.47–2.65 | 0.64 | |||
Diabetes mellitus | 1.58 | 0.55–3.61 | 0.33 | |||
Oral corticosteroids | 2.46 | 1.07–4.95 | 0.02 | |||
Inhaled corticosteroids | 5.70 | 1.97–13.1 | < 0.01 | 3.22 | 0.82–10.1 | 0.06 |
Immunosuppressants | 1.58 | 0.55–3.61 | 0.33 | |||
Albumin < 3.5 g/dL (N = 750) | 10.2 | 5.44–19.9 | < 0.01 | 5.89 | 3.01-12.0 | < 0.01 |
ESR elevation (N = 369) | 12.4 | 2.54–223 | 0.01 | |||
Lymphocyte count < 1000/µL (N = 827) | 3.02 | 1.69–5.37 | < 0.01 | |||
Mycobacterium avium | reference | |||||
Mycobacterium intracellulare | 1.98 | 1.12–3.68 | 0.02 | |||
Bronchiectasis | 2.10 | 0.97–5.49 | 0.09 | |||
Cavity formation | 3.52 | 2.02–6.11 | < 0.01 | |||
Cavity formation ≥ 2 cm | 5.13 | 2.82–9.07 | < 0.01 | 2.18 | 1.05–4.31 | 0.03 |
Cavity formation ≥ 2 lobes | 4.89 | 2.45–9.09 | < 0.01 | |||
Non-cavitary NB pattern | reference | |||||
Cavitary NB pattern | 4.23 | 2.30–7.79 | < 0.01 | |||
Fibrocavitary pattern | 1.99 | 0.32–6.80 | 0.35 | |||
